Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Virginia Kaklamani, MD, DSc

Research To Practice | Oncology Videos · Aug 23, 2026 · 14m

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 1: Identification of Appropriate Candidates with HR-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway; Role in the Up-Front Setting — Virginia Kaklamani, MD, DSc

CME information and select publications